Harshani Lawrence
Overview
Explore the profile of Harshani Lawrence including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhutada I, Khambati F, Cheng S, Tiek D, Duckett D, Lawrence H, et al.
Neuro Oncol
. 2023 Aug;
26(1):70-84.
PMID: 37551745
Background: Glioblastoma (GBM) is refractory to current treatment modalities while side effects of treatments result in neurotoxicity and cognitive impairment. Here we test the hypothesis that inhibiting CDK7 or CDK9...
2.
Mahajan S, Majumder A, Stewart P, Chen Y, Adhikari E, Fang B, et al.
ACS Chem Biol
. 2022 Mar;
17(4):776-784.
PMID: 35311290
To aid in the prioritization of deubiquitinases (DUBs) as anticancer targets, we developed an approach combining activity-based protein profiling (ABPP) with mass spectrometry in both non-small cell lung cancer (NSCLC)...
3.
Maccioni P, Kaczanowska K, Lawrence H, Yun S, Bratzu J, Gessa G, et al.
Front Cell Dev Biol
. 2021 Nov;
9:727576.
PMID: 34778249
Positive allosteric modulators (PAMs) of the GABA receptor (GABA PAMs) are of interest in the addiction field due to their ability to suppress several behaviors motivated by drugs of abuse....
4.
Rebecca V, Alicea G, Paraiso K, Lawrence H, Gibney G, Smalley K
Pigment Cell Melanoma Res
. 2014 Aug;
27(6):1154-8.
PMID: 25130256
The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset...
5.
Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, et al.
Prostate
. 2010 Jul;
70(12):1274-85.
PMID: 20623637
Background: Androgen receptor (AR) plays a critical role in the progression of both androgen-dependent and androgen-independent prostate cancer (AIPC). Ligand-independent activation of AR in AIPC or castration resistant prostate cancer...
6.
Kazi A, Lawrence H, Guida W, McLaughlin M, Springett G, Berndt N, et al.
Cell Cycle
. 2009 May;
8(12):1940-51.
PMID: 19471122
Numerous proteins controlling cell cycle progression, apoptosis and angiogenesis are degraded by the ubiquitin/proteasome system, which has become the subject for intense investigations for cancer therapeutics. Therefore, we used in...
7.
Ma Y, Kurtyka C, Boyapalle S, Sung S, Lawrence H, Guida W, et al.
Cancer Res
. 2008 Aug;
68(15):6292-9.
PMID: 18676853
HLM006474 was identified using a computer-based virtual screen and the known crystal structure of the DNA-bound E2F4/DP2 heterodimer. Treatment of multiple cell lines with HLM006474 resulted in the loss of...
8.
Su X, Vicker N, Lawrence H, Smith A, Purohit A, Reed M, et al.
J Steroid Biochem Mol Biol
. 2007 May;
104(3-5):312-20.
PMID: 17493801
11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) plays an important role in regulating the cortisol availability to bind to corticosteroid receptors within specific tissue. Recent advances in understanding the molecular mechanisms of...
9.
Su X, Lawrence H, Ganeshapillai D, Cruttenden A, Purohit A, Reed M, et al.
Bioorg Med Chem
. 2004 Jul;
12(16):4439-57.
PMID: 15265495
Extensive structural modifications to the 18beta-glycyrrhetinic acid template are described and their effects on the SAR of the 11beta-hydroxysteroid dehydrogenase isozymes type 1 and 2 from the rat are investigated....
10.
Vicker N, Su X, Lawrence H, Cruttenden A, Purohit A, Reed M, et al.
Bioorg Med Chem Lett
. 2004 May;
14(12):3263-7.
PMID: 15149687
Using 18beta-glycyrrhetinic acid as a template, the synthesis of a series of secondary amides at the 30-position is described and the effects of these modifications on the SAR of the...